Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance
Tania Calvo, Chantal Reina-Ortiz, David Giraldos, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Advances in NK cell production
Fang Fang, Siqi Xie, Minhua Chen, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 4, pp. 460-481
Open Access | Times Cited: 67
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Antonio Valeri, Almudena García-Ortiz, Eva Castellano, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 57
From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
Loïs Coënon, Martín Villalba
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
Natural Killer Cell-Mediated Immunotherapy for Leukemia
Michaela Allison, Joel Mathews, Taylor Gilliland, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 843-843
Open Access | Times Cited: 37
The metabolism of cells regulates their sensitivity to NK cells depending on p53 status
Sana Belkahla, Joaquín Marco-Brualla, Alexis Fayd’herbe de Maudave, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)
Nerea Allende-Vega, Joaquín Marco-Brualla, Paolo Falvo, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
Zonghan Wang, Wei Li, Hao Dong, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 13
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
Chantal Reina-Ortiz, Michael G. Constantinides, Alexis Fayd’herbe de Maudave, et al.
OncoImmunology (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 34
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Caroline Diorio, David T. Teachey, Stephan A. Grupp
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 4
CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma
Monica M. Cho, Longzhen Song, Aicha Quamine, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e008755-e008755
Open Access
A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis
Tao Fan, Zhiliang Lu, Yu Liu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Aicha Quamine, Mallery R. Olsen, Monica M. Cho, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2796-2796
Open Access | Times Cited: 23
Hsp70, in Combination with IL-15 and PD-1 Blocker, Interferes with The Induction of Cytotoxic NK Cells in Relapsed Acute Myeloid Leukemia Patients.
Javad Firouzi, Abbas Hajifathali, Masoumeh Azimi, et al.
PubMed (2023) Vol. 25, Iss. 2, pp. 92-101
Closed Access | Times Cited: 9
Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review)
Yongqin Zeng, Xiuzhi Lv, Juan Du
Oncology Reports (2021) Vol. 46, Iss. 5
Open Access | Times Cited: 22
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
Max Yano, John C. Byrd, Natarajan Muthusamy
Cancers (2022) Vol. 14, Iss. 23, pp. 5787-5787
Open Access | Times Cited: 14
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications
Paolo Sportoletti, Filomena De Falco, Beatrice Del Papa, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 6665-6665
Open Access | Times Cited: 19
Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies
Surojit Karmakar, Pradipta Pal, Girdhari Lal
ImmunoTargets and Therapy (2021) Vol. Volume 10, pp. 387-407
Open Access | Times Cited: 18
Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 392-392
Open Access | Times Cited: 13
Generation of non-genetically modified, CAR-like, NK cells
Loïs Coënon, Émilie Rigal, Hortense Courot, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e009070-e009070
Open Access | Times Cited: 2
Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro
Minna Sivonen, Katja A. Puttonen, Sara Wojciechowski, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1
Dang-Nghiem Vo, Nicolas Leventoux, Mauricio Campos‐Mora, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 688-688
Open Access | Times Cited: 7
Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?
Ofrat Beyar‐Katz, Dana Yehudai‐Ofir, Tsila Zuckerman
Acta Haematologica (2023) Vol. 147, Iss. 1, pp. 99-112
Open Access | Times Cited: 3
Effector and cytolytic function of natural killer cells in anticancer immunity
Surojit Karmakar, Amrita Mishra, Pradipta Pal, et al.
Journal of Leukocyte Biology (2023)
Closed Access | Times Cited: 2
The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cells
Martín Villalba, Michaël Constantinides, Loïs Coënon, et al.
Research Square (Research Square) (2024)
Open Access
CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma
Monica M. Cho, Longzhen Song, Aicha Quamine, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top